Key Takeaways
- Atossa Therapeutics’ Founder, Chairman, President, and CEO, Steven Quay, M.D., Ph.D., has been recognized as one of "The Top 50 Healthcare Technology CEOs of 2025" by The Healthcare Technology Report.
- Dr. Quay’s leadership has driven the development of innovative biotechnology solutions, including the company’s lead product candidate, (Z)-endoxifen.
- Atossa Therapeutics is focused on developing precision-based therapies for oncology and other areas of high unmet clinical need.
- The company is exploring the application of (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD) and is committed to fostering a culture that empowers its team to deliver lasting impact for patients.
Introduction to Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need. The company’s lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings. Atossa’s strategy emphasizes disciplined capital allocation, focusing resources on programs and data packages that can enable future regulatory submissions and potential commercialization. The company’s mission is to develop innovative medicines that can make a meaningful difference in the lives of patients.
Recognition of Dr. Steven Quay’s Leadership
Dr. Steven Quay, M.D., Ph.D., Founder, Chairman, President, and CEO of Atossa Therapeutics, has been selected as one of "The Top 50 Healthcare Technology CEOs of 2025" by The Healthcare Technology Report. This recognition is a testament to Dr. Quay’s leadership in advancing innovative biotechnology solutions and building a high-performing, people-centered organization. As a physician-scientist and entrepreneur, Dr. Quay has guided the development of (Z)-endoxifen across multiple Phase 2 clinical trials and throughout the full breast cancer treatment continuum. Under his direction, the therapy has been optimized as a potent selective estrogen receptor modulator/degrader (SERM/D) with additional PKCβ1 inhibition, designed to provide consistent systemic exposure independent of CYP2D6 metabolism.
Development of (Z)-Endoxifen
Atossa Therapeutics is committed to developing precision-based therapies for oncology and other areas of high unmet clinical need. The company’s lead product candidate, (Z)-endoxifen, is a precision-engineered endocrine therapy that has shown promising results in clinical trials. (Z)-endoxifen is designed to provide consistent systemic exposure independent of CYP2D6 metabolism, making it a potential treatment option for patients with breast cancer. The company is also exploring the application of (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness.
Company Culture and Mission
Atossa Therapeutics is committed to fostering a culture that empowers its team to deliver lasting impact for patients. The company’s mission is to develop innovative medicines that can make a meaningful difference in the lives of patients. Dr. Quay’s leadership has created a work environment that encourages collaboration, innovation, and a patient-centric approach. The company’s focus on people-centered organization and commitment to scientific rigor, strategic discipline, and a commitment to people have positioned it at the forefront of healthcare technology and life sciences advancement.
Forward-Looking Statements and Risks
The press release contains certain "forward-looking statements" within the meaning of applicable securities laws, including but not limited to, the company’s expectations regarding the development and regulatory strategy and related milestones, the potential indications that the company may pursue for (Z)-endoxifen, the potential for (Z)-endoxifen to receive regulatory approval and the timing thereof, and the potential market and growth opportunities for the company. These forward-looking statements are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with the company’s ability to successfully execute its strategy, the unpredictable relationship between preclinical study results and clinical study results, the timing or likelihood of regulatory filings and approvals, and other risks and uncertainties detailed from time to time in Atossa’s filings with the SEC.
Conclusion
In conclusion, Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of high unmet clinical need. The company’s lead product candidate, (Z)-endoxifen, is a precision-engineered endocrine therapy that has shown promising results in clinical trials. Dr. Steven Quay’s leadership has driven the development of innovative biotechnology solutions, and his recognition as one of "The Top 50 Healthcare Technology CEOs of 2025" is a testament to his commitment to advancing healthcare technology and life sciences advancement. The company’s focus on people-centered organization, commitment to scientific rigor, strategic discipline, and a commitment to people have positioned it at the forefront of healthcare technology and life sciences advancement.
